Clinical Trials

NCT Number: NCT01794403 Phase: Not Applicable Trial Summary: Accelerated Hypofractionation Radiotherapy for prostate cancer of 36.25 Gy delivered in 5 fractions will not be inferior to the standard treatment of 70.2 Gy given in 26 fractions – clinicaltrials.gov for more information and locations Clinicaltrials.gov Trial Sponsor(s): Acronym: HEAT

NCT Number: NCT02040610 Phase: Not Applicable Trial Summary: This study is being proposed to evaluate the use of moderate hypofractionated proton therapy in low and intermediate risk prostate cancer patients. Quality of life outcomes as well – clinicaltrials.gov for more information and locations Clinicaltrials.gov Trial Sponsor(s): Acronym:

NCT Number: NCT03933670 Phase: Phase 2 Trial Summary: This phase II trial studies the side how well hyperpolarized carbon C 13 pyruvate (HP C-13 pyruvate) magnetic resonance imaging (MRI) works in monitoring patients with prostate can – clinicaltrials.gov for more information and locations Clinicaltrials.gov Trial Sponsor(s): Acronym:

NCT Number: NCT04167969 Phase: Phase 1 Trial Summary: The purpose of this study is to see whether using the 64Cu-NOTA-PSMA-PEG-Cy5.5-C’ dot tracer is a safe way to identify tumor cells before and during surgery for prostate cancer. Th – clinicaltrials.gov for more information and locations Clinicaltrials.gov Trial Sponsor(s): Acronym:

NCT Number: NCT03824652 Phase: Phase 2 Trial Summary: This is a randomized control trial testing the effect of walnut supplementation on prostate cancer progression in 50 men with biopsy confirmed prostate cancer and planning to under – clinicaltrials.gov for more information and locations Clinicaltrials.gov Trial Sponsor(s): Acronym:

NCT Number: NCT02706561 Phase: Not Applicable Trial Summary: The purpose of this study is to test two different ways to help men with sexual rehabilita – clinicaltrials.gov for more information and locations Clinicaltrials.gov Trial Sponsor(s): Acronym:

NCT Number: NCT04025372 Phase: Phase 2 Trial Summary: This research study is comparing the use of a new form of hormonal therapy used with radiation as a possible treatment for intermediate risk prostate cancer. More specifically, thi – clinicaltrials.gov for more information and locations Clinicaltrials.gov Trial Sponsor(s): Acronym:

NCT Number: NCT03821246 Phase: Phase 2 Trial Summary: This phase II trial studies how well atezolizumab works alone or in combination with etrumadenant or tocilizumab in treating men with localized prostate cancer before radical prost – clinicaltrials.gov for more information and locations Clinicaltrials.gov Trial Sponsor(s): Acronym:

NCT Number: NCT04030559 Phase: Phase 2 Trial Summary: This phase II trial studies how well niraparib, when given before surgery, works in treating patients with high risk prostate cancer that has not spread to other parts of the body – clinicaltrials.gov for more information and locations Clinicaltrials.gov Trial Sponsor(s): Acronym:

NCT Number: NCT04194554 Phase: Phase 1|Phase 2 Trial Summary: The purpose of this study is to establish the maximum tolerable dose of niraparib when combined with prostate stereotactic body radiotherapy (SBRT), abiraterone, leuprolide, and pr – clinicaltrials.gov for more information and locations Clinicaltrials.gov Trial Sponsor(s): Acronym: ASCLEPIuS